First US-tested coronavirus vaccine fit for final trials

The first vaccine Covid-19 tested in the USA. Scientists announced Tuesday revived people’s immune systems just as scientists had expected — as the shots are poised to begin crucial final research. The experimental vaccine, developed by Fauci ‘s colleagues at the National Institutes of Health and Moderna Inc., will begin its most critical phase around July 27: A 30,000-person study to prove whether the shots are really good enough to defend against coronavirus.

But anxiously awaited results from the first 45 volunteers who rolled up their sleeves back in March, researchers announced Tuesday. Sure enough, the vaccine received an expected boost to the immune system. The research team stated in the New England Journal of Medicine that those early volunteers developed what are called bloodstream neutralizing antibodies — molecules essential to preventing infection — at rates comparable to those observed in people who survived COVID-19.

There is no guarantee but the government hopes to achieve results by the end of the year — record-setting speed for vaccine development. The vaccine demands two doses, one month apart. No significant side effects were reported. Yet more than half of the study participants reported flu-like reactions to the injection site shots that are not uncommon with other vaccinations — weakness, headache, chills , fever and pain. These reactions were more serious for 3 participants given the highest dose; that dose is not being followed.